


# Press release

Merger & Acquisition

29<sup>th</sup> of June, 2022



## Larka provided Cathay with a **Commercial Due Diligence** to support its investment in **TransCure.**



Advised by **Larka**

# Larka is thrilled to announce it performed the **Commercial Due Diligence** to support Cathay Capital's investment in **TransCure bioServices**, a global-leading Contract Research Organization (CRO) based in France.

While already established as a world-leading preclinical CRO specialized in humanized-mice models for in vivo pharmacology, this additional capital brought by Cathay Capital – paired with investments from TransCure's management team and Financière Arbevel – is set to further accelerate the already-sustained growth and global expansion of the biopharmaceutical player over the coming years.

## How Did Larka Support Cathay's Investment Process?



This Commercial Due Diligence provided Cathay Capital with **key insights and recommendations**, giving Larka a decisive role in the overall decision-making process, and in turn, the upcoming investment of the Franco-Chinese Private Equity firm in TransCure.

As for all of the M&A services provided by Larka to Private Equity firms, this Commercial Due Diligence process leveraged our teams' extensive life sciences industry and biopharmaceuticals knowledge – and in this case the **Drug Discovery universe and humanized-mice models** – to provide Cathay with a comprehensive picture of TransCure's:

- Services and core value proposition within the drug discovery landscape
- Humanized-mice CRO market dynamics & market value
- Positioning in the competitive landscape
- Customer environment and market feedbacks
- Business Plan review and growth avenues

**“We are delighted to be part of TransCure's exciting and ambitious development plan. During the process, Larka was both reactive and available for the team. Its contribution and deep healthcare knowledge have proven key for us in our understanding of TransCure's unique proposition and building our strong conviction about the company”.**

**Fabien Wesse**  
Managing Partner – Cathay Capital

### Contact Us

**Pierre-Anthony Brioir**  
Senior Director  
+33 650 630 286  
pabrioir@larka.com

**Adrien Chalmont**  
Senior Manager  
+33 621 006 115  
achalmont@larka.com

### Discover Related Services

**Commercial Due Diligence**

[Visit website](#) ▶

**Integrated Due Diligence**

[Visit website](#) ▶

**Operational Due Diligence**

[Visit website](#) ▶

**Technical Due Diligence**

[Visit website](#) ▶

## **About Cathay Capital**

Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than \$4.5 billion in assets, has completed over 220 buyouts, growth and venture capital investments with the global reach and local expertise from offices in Paris, New York, Shanghai, Munich, San Francisco, Beijing, Singapore, Shenzhen and Tel Aviv.

For more information, please visit [www.cathaycapital.com](http://www.cathaycapital.com)

## **About TransCure bioServices**

TransCure bioServices SAS is a European CRO based in France offering preclinical predictive in vivo pharmacology testing services to international large pharmaceutical, biotech and academic customers. Uniquely designed preclinical models with functional human immune system and human hepatocytes/liver provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV, Dengue), liver diseases, vaccines, and immuno-hepato toxicity (DMPK, ADME). If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver.

For more information, please visit [www.transcurebioservices.com](http://www.transcurebioservices.com)

## **About Larka**

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit [www.larka.com](http://www.larka.com)



**Larka**